Pipeline Peak 3: Clinical Validation of a New Therapeutic Target: Inhibiting Hyaluronan to Treat Lung Fibrosis & Pulmonary Hypertension

Time: 9:20 am
day: Day Two

Details:

  • Summarizing emerging data supporting the inhibition of the extracellular matrix glycosaminoglycan hyaluronan (HA) to address fibrotic pulmonary disease
  • Reviewing the results of phase 1 study investigating an HA synthesis inhibitor
  • Previewing two investigational Phase 2a studies of an HA inhibitor currently underway in pulmonary hypertension and progressive pulmonary fibrosis

Speakers: